How to Avoid Desk Rejection at International Journal of Molecular Sciences in 2026

Quick answer: International Journal of Molecular Sciences has a 2024 JIF of 4.9, ranks 72/319, and accepts about 38% of submissions. That makes it far more accessible than elite molecular biology journals, but not a free pass. Editors still reject manuscripts that are weakly molecular, underpowered, repetitive, or built on generic assay packages with inflated claims.

Related: How to avoid desk rejection • How to choose a journal • Pre-submission checklist

What IJMS editors actually scan for

They are asking three simple questions:

• Is there a real molecular question here?
• Is the evidence strong enough for the level of claim being made?
• Does this look like one more standard assay package, or a manuscript that actually teaches something?

The cover letter that gets desk rejected says something like: "We investigated the important role of pathway X in disease Y." That's not specific enough. Every disease paper says that. Editors want to know what exact mechanism, interaction, regulatory effect, or functional consequence you demonstrated.

How much gets desk rejected?

With overall acceptance around 38%, IJMS still rejects a lot of submissions. The difference from a journal like Advanced Materials is that the editorial bar is lower on glamour and higher on basic plausibility, scope, and evidence discipline. If the paper is clearly weak, it gets stopped. If it looks potentially workable, it often goes to review.

Desk rejection usually means the manuscript looked too routine, too weakly molecular, too incomplete, or too sloppily reported to justify reviewers. Peer review rejection means the paper passed the initial plausibility screen but then fell apart on controls, validation, statistics, or overinterpretation.

The main reasons IJMS desk rejects

1. Molecular language without real molecular depth

This is the biggest trap. Authors write "molecular" everywhere, but the actual manuscript is mostly clinical description, organismal phenotyping, nutritional observation, or pharmacological effect reporting. If the molecular component is superficial, editors notice fast.

Rejected example: a patient cohort paper that measures one serum biomarker and then claims new molecular insights into disease progression.

Stronger example: a cohort plus mechanistic validation showing how that biomarker regulates a pathway, target, or cellular response.

2. Routine assay bundles with overblown conclusions

There is a common IJMS manuscript template: qPCR, western blot, viability assay, migration assay, ROS measurement, then a huge mechanistic conclusion. Editors see this every day. If the paper looks like a standard package pasted onto a familiar biological claim, it may not survive triage.

What editors want is some sign that the paper goes beyond routine execution. A rescue experiment. Orthogonal validation. Better controls. Clinical or in vivo confirmation. Something that tightens the logic.

3. Bioinformatics-only or docking-only papers

These are high-risk unless done extremely well. Public databases and docking tools are useful, but they are not magic. If your whole story comes from TCGA, GEO, protein docking, or pathway enrichment without validation, the paper often reads as incomplete.

Editors are especially skeptical of:

• docking papers with no binding or functional assay
• multi-database signature papers with no independent validation cohort
• machine-learning biomarker claims with weak external testing

4. Familiar topic, no new angle

Another natural product induces apoptosis through PI3K/AKT. Another miRNA regulates inflammation. Another compound reduces oxidative stress. The space is crowded. Editors don't reject because the topic is familiar. They reject because the manuscript doesn't do enough to stand out inside a familiar topic.

5. Weak methods and reporting discipline

IJMS isn't Cell, but it still expects basic scientific seriousness. Missing replicates, vague antibodies, unclear statistics, image quality concerns, no correction for multiple testing, and unclear sample counts all trigger fast skepticism.

What editors scan for:

• how many biological replicates you actually had
• whether controls are appropriate
• whether the statistical tests match the design
• whether the figures look quantified and traceable

What desk rejection means here vs peer review rejection

If IJMS desk rejects the paper, the problem is usually structural: weak scope, weak evidence, thin mechanism, or a manuscript that feels too routine. If the paper reaches reviewers and then gets rejected, the criticism is often more granular: wrong control, overclaiming, lack of rescue, cell-line limitations, no clinical validation, no in vivo support, or an interpretation that outruns the data.

That distinction matters because a desk-rejected IJMS paper often needs reframing or retargeting, not just language editing.

What to fix before resubmitting

1. State the molecular question in one sentence. If that sentence is vague, your paper probably is too.
2. Add one orthogonal validation experiment. This helps more than another paragraph of discussion.
3. Cut claims your model can't support. Especially therapeutic, translational, or causal claims from narrow in vitro data.
4. Clean up reporting. Replicates, controls, antibodies, software, statistics, image handling.
5. Compare yourself to recent IJMS papers honestly. If your paper looks thinner, don't pretend the journal won't notice.

When to submit to IJMS, and when not to

Submit if:

• your paper has a genuine molecular mechanism, target, pathway, or structure-function story
• the evidence is more than routine assays or pure in silico inference
• the manuscript is broad enough for IJMS but still molecular at the core

Choose another journal if:

• the study is mostly clinical correlation with shallow molecular add-ons
• the work is docking-only, omics-only, or database-only with no validation
• the story is too narrow and routine even for a broad molecular journal

If that's your situation, a more specialized computational, pharmacology, disease-specific, or methods journal may be the better first move.

FAQ

Are special issues easier?
Sometimes faster, yes. Not immune to desk rejection, no.

Can single-cell-line studies still work?
Sometimes, but only with modest claims and strong mechanistic discipline.

Does IJMS want translational framing?
Only when the evidence supports it. Overplayed clinical significance backfires.

Will language polishing fix a likely desk rejection?
No. IJMS usually rejects on scientific framing, not sentence polish.

Sources

- International Journal of Molecular Sciences aims and scope, MDPI

• 2024 JCR metrics: JIF 4.9, Q1, rank 72/319
  
• IJMS editorial and author guidance documents
  
• Comparative review of recent IJMS publications in molecular medicine, signaling, omics, pharmacology, and bioinformatics